Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Takeda Pharmaceutical Ltd ADR (NY: TAK ) 14.33 -0.10 (-0.69%) Official Closing Price Updated: 7:00 PM EDT, Oct 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Takeda Pharmaceutical Ltd ADR < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization October 04, 2024 Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data... Via Benzinga Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines September 10, 2024 Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. Via Benzinga Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst September 09, 2024 HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... Via Benzinga Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production September 06, 2024 Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. Via Benzinga Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues August 12, 2024 FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient... Via Benzinga Exposures Product Safety Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday? August 07, 2024 Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP patients. Adzynma is the first enzyme replacement therapy in the EU for this... Via Benzinga TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024 July 31, 2024 Takeda Pharmaceutical just reported results for the first quarter of 2024. Via InvestorPlace 3 Biotech Stocks to Buy on the Dip: July 2024 July 29, 2024 Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. Via InvestorPlace Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation July 24, 2024 Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... Via Benzinga Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst July 09, 2024 Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to... Via Benzinga Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma July 06, 2024 Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was... Via Talk Markets Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report July 02, 2024 Blackstone Inc. is reportedly finalizing a deal to sell Alinamin Pharmaceutical to MBK Partners for $2.17 billion. Blackstone acquired Alinamin from Takeda in 2020. Via Benzinga Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 June 28, 2024 Protagonist Therapeutics will join the SmallCap 600 on Wednesday. Via Investor's Business Daily Topics Stocks Exposures US Equities NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session June 18, 2024 Via Benzinga Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 17, 2024 Via Benzinga What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? June 17, 2024 Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug. Via Benzinga Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies June 17, 2024 Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes Via Benzinga Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare June 15, 2024 Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi... Via Talk Markets 7 F-Rated Stocks to Avoid at All Costs in June June 06, 2024 The stock market is doing well this year, so it would be a tragedy to own F-rated stocks. Here are some key stocks to avoid in June. Via InvestorPlace Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report June 03, 2024 Blackstone reportedly considers sale of Japanese consumer healthcare firm Alinamin Pharmaceutical (previously owned by Takeda) for $1.9B, attracting interest from other firms. Via Benzinga Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings May 25, 2024 Via Talk Markets Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal May 19, 2024 In the headline deal, Takeda acquires global rights from AC Immune of Switzerland for $100 million upfront and up to $2.1B in milestones. Via Talk Markets Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement May 15, 2024 Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas. Via Benzinga Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? May 13, 2024 Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression. Via Benzinga Why Is AC Immune (ACIU) Stock Up 45% Today? May 13, 2024 AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical. Via InvestorPlace Catalyst's New CEO Has Big Ideas For The Small Biotech May 10, 2024 Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. Via Investor's Business Daily Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50% May 09, 2024 Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024. Via Benzinga TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023 May 09, 2024 Takeda Pharmaceutical just reported results for the fourth quarter of 2023. Via InvestorPlace Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder April 23, 2024 Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in... Via Benzinga No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win April 23, 2024 The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.